Beth Israel Deaconess Medical Center
Hematology and Oncology fellowship · Boston, MA · Program website
Roster not collected yet. There's no list of this program's own faculty, trainees, or papers yet. Below is Beth Israel Deaconess Medical Center's research in hematology and oncology, which the program shares with other departments and affiliated hospitals.
About Beth Israel Deaconess Medical Centerinstitution-wide hematology and oncology research
Hematology and Oncology publications from Beth Israel Deaconess Medical Center and affiliated institutions, since 2022. Updated 2026-11-07; refreshed daily.
251
works per year
23rd of 74 hematology and oncology fellowship programs
+10.3%
2-year growth
39th of 74 hematology and oncology fellowship programs
29.3%
in top 10% of field (works before 2025)
16th of 72 hematology and oncology fellowship programs
45.9%
cited above world average
26th of 72 hematology and oncology fellowship programs
Works per year · * 2026 so far
Oncology · 962Hematology · 294
Hematology and Oncology research topics at Beth Israel Deaconess Medical Center
Papers in the window; each links to the list on OpenAlex.
Most cited at Beth Israel Deaconess Medical Center since 2024
All hematology and oncology papers there on OpenAlex
- Overall Survival with Adjuvant Pembrolizumab in Renal-Cell CarcinomaToni K. Choueiri et al. · New England Journal of Medicine · 2024 · PubMed · cited 365
- Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trialNizar M. Tannir et al. · Annals of Oncology · 2024 · PubMed · cited 236
- The tumor microenvironment’s role in the response to immune checkpoint blockadeKonstantinos Aliazis et al. · Nature Cancer · 2025 · PubMed · cited 203
- Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trialAndrea J. Bullock et al. · Nature Medicine · 2024 · PubMed · cited 159
- Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple MyelomaSundar Jagannath et al. · Journal of Clinical Oncology · 2025 · PubMed · cited 152
- SOX17 enables immune evasion of early colorectal adenomas and cancersNorihiro Goto et al. · Nature · 2024 · PubMed · cited 116
- Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 studyMohamad Ezzeddine Allaf et al. · The Lancet Oncology · 2024 · PubMed · cited 101
- Immune checkpoint inhibitor-associated myocarditis: a novel risk scoreJohn R. Power et al. · European Heart Journal · 2025 · PubMed · cited 90
- A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancerMohamed Alaa Gouda et al. · ESMO Open · 2025 · PubMed · cited 88
- Precision therapeutics and emerging strategies for HR-positive metastatic breast cancerMaxwell Roger Lloyd et al. · Nature Reviews Clinical Oncology · 2024 · PubMed · cited 79